By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
latest_posts
- 1
80 km. on foot: Sharren Haskel’s three-day march in protest of haredi draft bill - 2Novo Nordisk cuts Wegovy price in South Africa for a second time
- 3The Job of a Land Legal counselor in Property Exchanges
- 4Allow Innovative Progressions To have a Tremendous Effect
- 5Lebanese Shi’a party Amal competing, coordinating with Hezbollah, experts tell ‘Post’
- Manual for Tracking down the Mysterious Cascades in China
- Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- Volkswagen Plant Could Pivot From Building Cars to Supporting Iron Dome Systems
- Posts falsely claim Malaysian minister to relocate public hospital for temple
- Former defense minister Gallant vacated home over security threat under Shin Bet direction
- Audits of the Top Science fiction Movies This Year
- Oil rises above $115 and Asia stocks slide as Iran war escalates
- German state railway loss widens, passengers warned of trouble ahead
- Former ‘Dancing with the Stars’ Pro Survives Plane Crash at LaGuardia That Left 2 Pilots Dead
